BRIACELL THERAP (BCTX)
(Delayed Data from NSDQ)
$0.81 USD
-0.43 (-34.68%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $0.84 +0.03 (3.70%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for BRIACELL THERAP falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 21 | 41 | 57 | 0 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 1 | 1 | 0 |
Total Current Assets | NA | 27 | 42 | 58 | 0 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 27 | 43 | 58 | 0 |
Liabilities & Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 0 | 1 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 2 | 1 | 1 | 4 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 29 | 31 | 0 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 31 | 32 | 1 | 4 |
Shareholders Equity | 7/31/2024 | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 70 | 66 | 55 | 11 |
Capital Surplus | NA | 0 | 5 | 0 | 0 |
Retained Earnings | NA | -81 | -60 | -16 | -17 |
Other Equity | NA | 7 | 0 | 18 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -4 | 10 | 57 | -3 |
Total Liabilities & Shareholder's Equity | NA | 27 | 43 | 58 | 0 |
Total Common Equity | 0 | -4 | 10 | 57 | -3 |
Shares Outstanding | 18.20 | 15.90 | 15.50 | 15.20 | 0.70 |
Book Value Per Share | 0.00 | -0.24 | 0.67 | 3.77 | -4.70 |
Fiscal Year End for BRIACELL THERAP falls in the month of July.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 6 | 14 | 21 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 5 | 5 | 5 | 6 |
Total Current Assets | NA | 6 | 12 | 18 | 27 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 6 | 12 | 19 | 27 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 4 | 0 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 7 | 4 | 1 | 2 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 17 | 15 | 29 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 12 | 21 | 16 | 31 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 70 | 70 | 70 | 70 |
Capital Surplus | NA | 0 | 0 | 8 | 0 |
Retained Earnings | NA | -84 | -86 | -75 | -81 |
Other Equity | NA | 8 | 8 | 0 | 7 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -6 | -8 | 3 | -4 |
Total Liabilities & Shareholder's Equity | NA | 6 | 12 | 19 | 27 |
Total Common Equity | 0 | -6 | -8 | 3 | -4 |
Shares Outstanding | 18.20 | 15.90 | 15.90 | 15.90 | 15.90 |
Book Value Per Share | 0.00 | -0.39 | -0.52 | 0.16 | -0.24 |